Ein leeres Büro. Durch das Fenster sieht man die Gebäude der Curevac, davor eine Baustelle

Unsere Forschungsgruppe zieht im März um. Heute Besichtigung des neuen Büros - mit direktem Blick auf #Curevac (bzw. jetzt #Biontech).
Davor wird allerdings ein weiteres Gebäude hochgezogen.

BioNTech Completes CureVac Acquisition, Expanding Its mRNA Platform BioNTech SE ( NASDAQ: BNTX) has completed its acquisition of CureVac N.V., closing its public exchange offer and moving toward full integration of the two mRNA

#BioNTech ( #BNTX) has closed its roughly $1.25 billion all‑stock acquisition of #CureVac, bringing in CureVac’s mRNA design, LNP delivery, and manufacturing assets to deepen BioNTech’s oncology‑focused mRNA platform.
prismmarketview.com/biontech-com...

BioNTech übernimmt CureVac Der Biotechkonzern BioNTech schließt die Übernahme von CureVac ab.

BioNTech übernimmt CureVac #BioNTech #CureVac #Übernahme

Kartellamt erlaubt BioNTech die Übernahme von CureVac In der Corona-Pandemie waren sie noch Konkurrenten: Jetzt hat das Bundeskartellamt seine Erlaubnis zur Übernahme des Tübinger Impfstoff-Entwicklers CureVac durch den Mainzer Konkurrenten BioNTech gegeben.

Na, guck einer an:

„#BioNTech darf #CureVac übernehmen“

www.tagesschau.de/wirtschaft/unternehmen/b...

BioNTech darf CureVac übernehmen Das Bundeskartellamt sieht den Wettbewerb durch die Übernahme nicht gefährdet.

BioNTech darf CureVac übernehmen #BioNTech #CureVac #Übernahme

#BioNTech's takeover of #CureVac seems to have unlocked a resolution to some of the patent litigation swirling around #mRNA vaccine technologies.

pharmaphorum.com/news/gsk-and...

CureVac Among 3 Promising Penny Stocks To Watch - Yahoo.co CureVac Among 3 Promising Penny Stocks To Watch  Yahoo.co

Click Subscribe #CureVac #PennyStocks #Investing #StockMarket #FinanceNews

Den Kläger einfach kaufen 💪

#curevac #biontech

💉Biontech Şimdi De Kansere Deva Arıyor..🇹🇷
.
#biontech #curevac #kanser #tıp #sağlık #ekonomi #dünya #almanya #asj #tamerışıtır #allstreetjournal

BioNTech приобретет CureVac за $1,25 млрд в рамках сделки с оплатой акциями | Новости фармотрасли | GxP News Немецкий фармгигант BioNTech согласился приобрести своего отечественного конкурента CureVac за $1,25 млрд. Сделка положит конец патентным разбирательствам. Новости фармотрасли GxP News.

BioNTech приобретет CureVac за $1,25 млрд в рамках сделки с оплатой акциями Немецкий фармгигант BioNTech согласился прио...

#Новости #Новости #фармотрасли #BioNTech #CureVac

Origin | Interest | Match

BioNTech übernimmt ehemaligen COVID-Impfstoff-Rivalen CureVac Das deutsche Biotechnologieunternehmen BioNTech gab am Donnerstag bekannt, dass es sich mit dem heimischen Konkurrenten CureVac auf eine Übernahme geeinigt hat. Der Kaufpreis beläuft sich auf rund...

#BioNTech übernimmt ehemaligen COVID-Impfstoff-Rivalen #CureVac de.marketscreener.com/kurs/aktie/B...

Halper Sadeh LLC Launches Investigation into Potential Securities Violations for CureVac, Volato Group, and M2i Global Halper Sadeh LLC is investigating possible securities law violations involving CureVac, Volato Group, and M2i Global. Shareholders are encouraged to learn more about their rights.

Halper Sadeh LLC Launches Investigation into Potential Securities Violations for CureVac, Volato Group, and M2i Global #United_States #New_York #CureVac #Volato_Group #M2i_Global

BionTech dev rakibini 1.25 milyar dolara satın alıyor Alman ilaç firması BioNTech, büyüyen onkoloji bölümü için Covid aşısı üreten rakibi CureVac NV'yi yaklaşık 1,25 milyar dolara satın alacağını açıkladı. Anlaşma, Covid aşısı geliştirme yarışı sırasında doruğa ulaşan iki şirket arasındaki onlarca yıllık rekabeti sonlandırıyor. Covid-19 pandemisi sırasında BioNTech, ortağı Pfizer Inc. ile aşı yarışını kazanarak Avrupa'nın önde gelen biyoteknolojilerinden birine dönüştü. CureVac'ın aşısı, klinik deneylerde daha az etkili olduğu kanıtlandıktan sonra asla piyasaya sürülmedi.  KANSER ARAŞTIRMALARINA ODAKLANMIŞTI Bloomberg'e göre CureVac bulaşıcı hastalık çalışmalarından uzaklaşarak bunun yerine kanser araştırmalarına odaklandı. Devralma, BioNTech'in kanser araştırmalarına yatırım için attığı bir dizi adımın sonuncusu. Şirket bu ayın başlarında Bristol-Myers Squibb Co.'ya 11,1 milyar dolara kadar yeni nesil bir kanser ilacı lisansladı. HİSSELERİ TAVAN YAPTI CureVac hisseleri ABD borsaları açılmadan önce yüzde 26 artarken BioNTech hisseleri ise yüzde 1,5 yükseldi.  Anlaşma ayrıca, pandemi sırasında hisse aldıktan sonra CureVac'ın yüzde 13,3'üne sahip olan Alman hükümeti için bir çıkış anlamına geliyor. Anlaşmanın şartları uyarınca BioNTech hisselerinden yaklaşık 163 milyon dolar alacak. BioNTech'e göre Alman hükümeti, devralma işlem hakkında olumlu bir görüşe sahip. BioNTech, anlaşmayı desteklemek için CureVac'ın hissedarlarının yarısından biraz fazlasından sözleşmesel taahhütler bekliyor. Bunlar arasında, yazılım devi SAP SE'nin kurucu ortağı olan Alman milyarder Dietmar Hopp da yer alıyor. Kaynak: HABER7.COM#ESHAHABER.COM.TR #haber #gündem #sondakika #news #press #worldnews

Güncel News press BionTech dev rakibini 1.25 milyar dolara satın alıyor #BionTech #CureVac #Covid19 #KanserAraştırmaları #Onkoloji

BioNTech to buy rival mRNA firm CureVac for $1.25bn BioNTech has agreed to buy another specialist in mRNA medicines, fellow German biotech CureVac, for around $1.25 billion.

#BioNTech has agreed to buy another specialist in #mRNA-based vaccines and therapeutics, fellow German biotech #CureVac, in an all-stock #deal valued at around $1.25 billion.

Der Bund als "Unternehmer" bzw. Sachwalter von Steuergeld (Teil 3.457): Aus einer 300 Millionen Euro schweren Beteiligung an #Curevac erhält man nun, fünf Jahre später, für rund 140 Millionen Euro #Biontech-Aktien. To be continued...

BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals - Reuters BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals  Reuters

Click Subscribe #BioNTech #CureVac #COVID19 #vaccine #biotech

BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals By Ludwig Burger (Reuters) -German biotech firm BioNTech (NASDAQ:BNTX) has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments. Under the deal, which pairs two former rivals in the race to develop COVID-19 vaccines, CureVac shareholders stand to receive a premium of 55% over the three-month average share price, and leave them with a stake of about 4%-6% in BioNTech, the suitor said. CureVac’s Frankfurt-listed shares surged 27% to a five-month high, valuing the company at 1.04 billion euros ($1.2 billion), while BioNTech shares were down 2% by 1237 GMT. The deal further underscores BioNTech’s long-term pursuit of new cancer treatments as it aims to show that its success as Pfizer (NYSE:PFE)’s COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke. "With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," it said. CureVac opted to focus on oncology about a year ago when it agreed to sell its remaining influenza and COVID-19 vaccine development to alliance partner GSK. It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic. GERMAN BIOTECH CHAMPION The agreement is also set to end CureVac’s years-long legal fight over alleged mRNA patent infringement by BioNTech and for a share of vaccine revenues, where CureVac has made little progress. CureVac shares were worth as much as 120 euros in December 2020 on hopes it would develop a COVID vaccine, more than double their initial public offer value in August of that year. They are now trading at 4.65 euros. BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers (NYSE:BMY) Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co (NYSE:MRK)’s best-selling drug Keytruda. Each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, but subject to a so-called collar mechanism, BioNTech said. If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476. BioNTech said the deal was supported by SAP SE (ETR:SAPG) co-founder and football investor Dietmar Hopp, who holds a stake of about 37% in CureVac. The German government, owner of about 13% in CureVac for its financial backing during the pandemic, said it welcomed in principle the creation of a "new German biotech champion", and that it would review the offer. ($1 = 0.8624 euros) MRK: A Bull or Bear Market Play? Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year.. In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if MRK is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.

Click Subscribe #BioNTech #CureVac #COVID19 #VaccineDevelopment #PharmaNews

Biontech: Curevac-Aktie schießt nach Übernahmeofferte hoch Sie waren lange Zeit Konkurrenten im Wettlauf um einen Coronaimpfstoff, jetzt will das Unternehmen von Uğur Şahin den Rivalen übernehmen. Der Deal könnte ein weiterer Schritt in Richtung Marktreife wi...

Dat is interessant. #Biontech wil #Curevac overnemen. Beide zijn experts op het gebied van #mRNA-onderzoek. Biontech lukte het al snel een werkend coronavaccin te maken, Curevac niet. Maar de grote vissen komen nog in de vorm van kankermedicijnen www.manager-magazin.de/unternehmen/...

Biontech übernimmt Konkurrenten Curevac – und das sind die Gründe Übernahme auf dem deutschen Pharmamarkt. Biontech übernimmt den Konkurrenten Curevac. Das Mainzer Unternehmen stößt damit weiter vor auf einen lukrativen Markt.

#Biontech übernimmt #Curevac. Für #Tübingen ist das erstmal eine gute Nachricht.

www.t-online.de/finanzen/akt...

Germany’s BioNTech to buy CureVac to boost cancer research

Germany’s BioNTech to buy CureVac to boost cancer research Germany’s BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutic...

#Business #biontech #CureVac #Germany #pharmaceutical

Origin | Interest | Match

BioNTech übernimmt deutschen Rivalen CureVac BioNTech will als Investition in die Zukunft der Krebsmedizin seinen Konkurrenten CureVac übernehmen.

BioNTech übernimmt deutschen Rivalen CureVac #BioNTech #CureVac #Übernahme

CureVac stock soars about 30% after BioNTech agrees to acquire co Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #CureVac #BioNTech #StockMarket #Investing #Biotech

BioNTech will CureVac übernehmen: Milliarden-Deal im deutschen Biotech-Sektor BioNTech plant die vollständige Übernahme des Tübinger Biotech-Unternehmens CureVac. Der Deal ist interessant, denn beide Unternehmen liefern sich seit Längerem einen bisher nicht abgeschlossenen

BioNTech will CureVac übernehmen: Milliarden-Deal im deutschen Biotech-Sektor ... www.4investors.de/nachrichten/... #biontech #curevac #biotech $BNTX $CVAC #4investors

So kann man den Patentstreit natürlich auch beilegen... investors.biontech.de/de/news-rele... #biontech #curevac

CureVac Among 3 Promising Penny Stocks To Watch - Yahoo Finance CureVac Among 3 Promising Penny Stocks To Watch  Yahoo Finance

Click Subscribe #StockMarket #Investing #PennyStocks #Finance #CureVac

CureVac Aktie wackelt: Eine kritische Phase - und nun? Die CureVac Aktie hat es erneut nicht geschafft, Kursgewinne aus einer dynamischen Rallye zu verteidigen - wie bereits im Jahr 2024, da führte ein Anstieg auf 5,28 Dollar nicht zu einer nachhaltigen

CureVac Aktie wackelt: Eine kritische Phase - und nun? ... www.4investors.de/nachrichten/... #curevac #aktien $cvac #4investors

CureVac Aktie testet 200-Tage-Linie: Kommt neuer Kursschub? Die CureVac Aktie hat sich seit den beiden Baissetiefs aus dem Jahr 2024 bei 2,22/2,37 Dollar zuletzt wieder spürbar erholt. Die jüngste Rallye startete bei 2,37 Dollar und führte den Kurs am 7.

CureVac Aktie testet 200-Tage-Linie: Kommt neuer Kursschub? ... www.4investors.de/nachrichten/... #curevac #aktien $cvac #4investors

Meaning of #curevac It is a company, its founder is Iron Inmar was founded in 2000.. curevac

Meaning of #curevac Name of a German laboratory conducting research on a Coronavirus vaccine... curevac

Meaning of #curevac SPAM for a biotech laboratory... curevac